Skin Infection Drug Requirements Eased in Final FDA Guidance

Clinical Trials Advisor
While the FDA generally requires two Phase III trials to support approval of drugs to treat acute bacterial skin and skin structure infections (ABSSSI), an Oct. 16 final guidance says a single Phase III study that is supported by additional independent evidence may suffice.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00